Phaseline

Companies › Quell Therapeutics

Quell Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Gastroenterology, Immunology; next expected readout Aug 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
QEL-005
autologous CAR-T regulatory cell therapy targeting CD19 on B cells
–Phase 1Diffuse Cutaneous Systemic SclerosisAug 2028
QEL-001
CAR-Treg (chimeric antigen receptor-engineered regulatory T cell) targeting HLA-A2
HLA-A2Phase 1Rejection; Transplant, LiverSep 2040

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07473154QEL-005Phase 1Diffuse Cutaneous Systemic SclerosisImmunologyAug 2028
NCT05234190QEL-001Phase 1Rejection; Transplant, LiverGastroenterologySep 2040

Targets

HLA-A2 (1)

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.